Literature DB >> 19939230

The hyperforin derivative IDN5706 occludes spatial memory impairments and neuropathological changes in a double transgenic Alzheimer's mouse model.

W Cerpa1, J L Hancke, P Morazzoni, E Bombardelli, Antonella Riva, P P Marin, Nibaldo C Inestrosa.   

Abstract

The use of natural compounds is an interesting stratagem in the search of drugs with therapeutic potential for the treatment of Alzheimer's disease (AD). We report here the effect of the hyperforin derivative (IDN5706, tetrahydrohyperforin), a semi-synthetic derivative of the St. John's Wort, on the brain neuropathology, learning and memory in a double transgenic (APPswe, PS-1dE9) mouse model of AD. Results indicate that, IDN5706 alleviates memory decline induced by amyloid-beta (Abeta) deposits as indicated by the Morris water maze paradigm. Moreover, the analysis of Abeta deposits by immunodetection and thioflavin-S staining of brain sections, only reveals a decrease in the frequency of the larger-size Abeta deposits, suggesting that IDN5706 affected the turnover of amyloid plaques. Immunohistochemical analysis, using GFAP and n-Tyrosine indicated that the hyperforin derivative prevents the inflammatory astrocytic reaction and the oxidative damage triggered by high Abeta deposit levels. We conclude that the hyperforin derivative, IDN5706, has therapeutic potential for prevention and treatment of AD.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19939230     DOI: 10.2174/156720510790691218

Source DB:  PubMed          Journal:  Curr Alzheimer Res        ISSN: 1567-2050            Impact factor:   3.498


  17 in total

1.  Derivatives of Piperazines as Potential Therapeutic Agents for Alzheimer's Disease.

Authors:  Elena Popugaeva; Daria Chernyuk; Hua Zhang; Tatyana Y Postnikova; Karina Pats; Elena Fedorova; Vladimir Poroikov; Aleksey V Zaitsev; Ilya Bezprozvanny
Journal:  Mol Pharmacol       Date:  2019-01-29       Impact factor: 4.436

Review 2.  Dysregulation of neuronal calcium homeostasis in Alzheimer's disease - A therapeutic opportunity?

Authors:  Elena Popugaeva; Ekaterina Pchitskaya; Ilya Bezprozvanny
Journal:  Biochem Biophys Res Commun       Date:  2016-09-15       Impact factor: 3.575

3.  Reduced TRPC6 mRNA levels in the blood cells of patients with Alzheimer's disease and mild cognitive impairment.

Authors:  R Lu; J Wang; R Tao; J Wang; T Zhu; W Guo; Y Sun; H Li; Y Gao; W Zhang; C J Fowler; Q Li; S Chen; Z Wu; C L Masters; C Zhong; N Jing; Y Wang; Y Wang
Journal:  Mol Psychiatry       Date:  2017-07-11       Impact factor: 15.992

4.  Store-Operated Calcium Channel Complex in Postsynaptic Spines: A New Therapeutic Target for Alzheimer's Disease Treatment.

Authors:  Hua Zhang; Suya Sun; Lili Wu; Ekaterina Pchitskaya; Olga Zakharova; Klementina Fon Tacer; Ilya Bezprozvanny
Journal:  J Neurosci       Date:  2016-11-23       Impact factor: 6.167

5.  Reduced Alzheimer's disease pathology by St. John's Wort treatment is independent of hyperforin and facilitated by ABCC1 and microglia activation in mice.

Authors:  Jacqueline Hofrichter; Markus Krohn; Toni Schumacher; Cathleen Lange; Björn Feistel; Bernd Walbroel; Hans-Jochen Heinze; Sara Crockett; Timothy F Sharbel; Jens Pahnke
Journal:  Curr Alzheimer Res       Date:  2013-12       Impact factor: 3.498

6.  Reversal of Calcium Dysregulation as Potential Approach for Treating Alzheimer's Disease.

Authors:  Elena Popugaeva; Daria Chernyuk; Ilya Bezprozvanny
Journal:  Curr Alzheimer Res       Date:  2020       Impact factor: 3.498

Review 7.  Dysregulation of Intracellular Calcium Signaling in Alzheimer's Disease.

Authors:  Elena Popugaeva; Ekaterina Pchitskaya; Ilya Bezprozvanny
Journal:  Antioxid Redox Signal       Date:  2018-08-03       Impact factor: 8.401

8.  Interactions of AChE with Aβ Aggregates in Alzheimer's Brain: Therapeutic Relevance of IDN 5706.

Authors:  Francisco J Carvajal; Nibaldo C Inestrosa
Journal:  Front Mol Neurosci       Date:  2011-09-14       Impact factor: 5.639

Review 9.  Reactive astrocytes as treatment targets in Alzheimer's disease-Systematic review of studies using the APPswePS1dE9 mouse model.

Authors:  Tamar Smit; Natasja A C Deshayes; David R Borchelt; Willem Kamphuis; Jinte Middeldorp; Elly M Hol
Journal:  Glia       Date:  2021-02-25       Impact factor: 7.452

10.  Tetrahydrohyperforin prevents cognitive deficit, Aβ deposition, tau phosphorylation and synaptotoxicity in the APPswe/PSEN1ΔE9 model of Alzheimer's disease: a possible effect on APP processing.

Authors:  N C Inestrosa; C Tapia-Rojas; T N Griffith; F J Carvajal; M J Benito; A Rivera-Dictter; A R Alvarez; F G Serrano; J L Hancke; P V Burgos; J Parodi; L Varela-Nallar
Journal:  Transl Psychiatry       Date:  2011-07-12       Impact factor: 6.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.